Pfizer said it issued a press release on August 5, 2025 announcing its financial results for Q2 2025, which it submitted as Exhibit 99 pursuant to Item 2.02.

1. 01

   Pfizer said it issued a press release on August 5, 2025 announcing its financial results for Q2 2025, which it submitted as Exhibit 99 pursuant to Item 2.02.

2. 02

   The company said the information provided pursuant to Item 2.02, including Exhibit 99, shall not be deemed to be "filed" under Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into any other filing except as expressly set forth by specific reference.

3. 03

   Pfizer disclosed that it registered with the New York Stock Exchange common stock with a par value of $0.05 (PFE) and notes due 2027 at 1.000%, notes due 2029 at 2.875%, notes due 2032 at 3.250%, notes due 2037 at 3.875%, and notes due 2045 at 4.250%.

4. 04

   The company presented as exhibits to this 8-K a press release dated August 5, 2025 (Exhibit 99) and a cover page Inline XBRL data file (Exhibit 104), signed by Margaret M. Madden, Senior Vice President and Corporate Secretary.

Analysis scope · Filing body only (exhibits excluded)We analyzed the filing body only. The exhibits exceeded the length limit and were excluded, so figures, financial statements and presentation materials in them were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.